Generate Biomedicines (NASDAQ:GENB) Sees Large Volume Increase – Time to Buy?

Shares of Generate Biomedicines Inc (NASDAQ:GENB) saw unusually-high trading volume on Wednesday . 836,226 shares were traded during trading, an increase of 16% from the previous session’s volume of 719,495 shares.The stock last traded at $18.1910 and had previously closed at $20.38.

Analyst Ratings Changes

GENB has been the topic of a number of research reports. HC Wainwright lifted their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Weiss Ratings assumed coverage on Generate Biomedicines in a research report on Tuesday, August 11th. They issued a “sell (d)” rating for the company. Morgan Stanley boosted their target price on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Stock Down 2.3%

The firm has a market cap of $2.02 billion and a P/E ratio of -9.92. The firm’s 50 day moving average is $15.26.

Generate Biomedicines (NASDAQ:GENB) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million for the quarter. As a group, research analysts expect that Generate Biomedicines Inc will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of Generate Biomedicines

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Braidwell LP bought a new position in Generate Biomedicines in the 2nd quarter worth about $55,398,000. Bank of New York Mellon Corp bought a new stake in shares of Generate Biomedicines during the second quarter valued at about $967,000. AXQ Capital LP purchased a new stake in shares of Generate Biomedicines in the second quarter worth about $218,000. Susquehanna International Group LLP purchased a new stake in shares of Generate Biomedicines in the second quarter worth about $196,000. Finally, California State Teachers Retirement System bought a new position in shares of Generate Biomedicines in the second quarter valued at approximately $96,000.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.